A Phase 3, Randomized, Open-Label, Multicenter, Global Study of the Efficacy and Safety of Durvalumab (D) plus Tremelimumab (T) plus Enfortumab Vedotin (Ev) or D plus Ev for Neoadjuvant Treatment in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (Mibc) (Volga).

AuthID
 P-00W-E6W
12
Author(s)
Drakaki, A
·
Teoh, JYC
·
Grande, E
·
Porta, C
·
Wu, E
·
Ho, S
·
Hois, S
·
Document Type
Abstract
Year published
2022
Published
in JOURNAL OF CLINICAL ONCOLOGY, ISSN: 0732-183X
Volume: 40, Issue: 6
Indexing
Wos®
Google Scholar®
Publication Identifiers
Wos: WOS:000771008900586
Source Identifiers
ISSN: 0732-183X
Export Publication Metadata
Marked List
 Add to Marked List
Info
At this moment we don't have any links to full text documens.

A place for researchers and their institutions

Useful Links

Get Help

© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service